SYDNEY--(BUSINESS WIRE)--Jun 11, 2019--

SpeeDx Pty. Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for Resistance Plus® GC* - expediting the path towards FDA clearance. Resistance Plus® GC is the first commercially available molecular test providing ciprofloxacin susceptibility and resistance information to effectively treat the sexually transmitted infection (STI) N.gonorrhea. It is already CE-marked and cleared by the Therapeutic Goods Association (TGA) for use across Europe, Australia and New Zealand. It detects both the sexually transmitted infection N. gonorrhea and sequences in the gyr A gene of the bacteria associated with susceptibility or resistance to ciprofloxacin, a previously used front-line antibiotic treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005313/en/

Results from ResistancePlus GC can be used to guide treatment decisions for gonorrhea infections, giving doctors and patients the option of using a simple oral dose of ciprofloxacin instead of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant infections. (Photo: Business Wire)

Results from the test can be used to guide treatment decisions for gonorrhea infections, giving doctors and patients the option of using ciprofloxacin instead of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant infections.

“There is an urgent need for better diagnostics to address the problem of drug-resistant gonorrhea in the United States,” said Dr. Jeffrey Klausner, Professor of Medicine and Public Health at David Geffen School of Medicine and Fielding School of Public Health, University of California, Los Angeles. “Drug-resistant gonorrhea is an urgent public health problem.”

The FDA Breakthrough Devices Program is intended to help patients have more timely access to medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases by expediting their development, assessment, and review.

“We are very pleased that the FDA has recognised Resistance Plus GC as an important tool for the ongoing arms race against gonorrhea and rising antibiotic resistance,” said Colin Denver, SpeeDx CEO. “The results from our tests empower clinicians to make better informed treatment decisions, and we are passionate about the responsible use and stewardship of antibiotics to achieve the best possible patient outcomes.”

Ceftriaxone, a painful intramuscular injection, is the current front-line treatment for gonorrhea, however resistance has already been reported in Europe and Australia 1,2 and experts are concerned that we may quickly run out of treatment options altogether. 3 Recent surveillance data indicates that in some regions up to 7 out of 10 infections could be effectively treated with a single, more convenient oral dose of ciprofloxacin if the susceptibility status is established prior to prescribing. 4-6 The British Association of Sexual Health and HIV (BASHH) have recognised the importance of antibiotic stewardship in their recently updated gonorrhea management guidelines, preferring the use of ciprofloxacin over ceftriaxone if antibiotic susceptibility results are available prior to treatment. 7

“SpeeDx tests can help make antibiotic-resistance guided therapy a reality, giving doctors real time information to make smarter antibiotic treatment choices,” adds Dr. Klausner.

Besides developing antibiotic resistance testing for gonorrhea, SpeeDx is also conducting multi-site clinical trials for the Resistance Plus® MG test (not currently available for sale in the U.S.). The molecular test detects the rapidly rising STI Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the frontline antibiotic treatment, azithromycin.

*Not available in the U.S.

About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see https://plexpcr.com.

References

1. PHE Health Protection Report Volume 12, Number 11. 2018
2. AU DoH Media Statement April 17th 2018.
3. Unemo, M. & Jensen, J.S. 2016. Nat. Rev. Urol..268. Published online 10 Jan 2017. doi:10.1038/nrurol
4. Eyre DW et al. Euro Surveill. 2019;24(10): pii=1900147.
5. Harris SR et al. Lancet Infect Dis Published online May 15th, 2018
6. Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
7. Fifer et al. British Association for Sexual Health and HIV national guideline for the management of infection with Neisseria gonorrhoeae (2019).

View source version on businesswire.com:https://www.businesswire.com/news/home/20190611005313/en/

CONTACT: Asia Pacific and Europe

Global Marketing Manager

Madeline O’Donoghue

[email protected]

+61 2 9209 4170United States

RCI Healthcare Public Relations

Rick Roose

[email protected]

+1 415 202 4445

KEYWORD: AUSTRALIA AUSTRALIA/OCEANIA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES MEDICAL DEVICES PHARMACEUTICAL FDA

SOURCE: SpeeDx Pty. Ltd.

Copyright Business Wire 2019.

PUB: 06/11/2019 08:00 AM/DISC: 06/11/2019 08:01 AM

http://www.businesswire.com/news/home/20190611005313/en